InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

20 October 2025

Name:

BARD1 LIFE SCIENCES LIMITED (BD1)
(This company subsequently changed its name to INOVIQ LTD. You should refer to that name for Status.)

ISIN:

AU000000BD12

Date of Listing:

18 April 1991

Subsequent Names:

Company Name	Start Date	End Date
INOVIQ LTD	09/12/2021

Former Names:

Stock Exchange Status: (updated daily)

This company subsequently changed its name to INOVIQ LTD. You should refer to that name for Stock Exchange Status.

Legal Status: (updated monthly)

ACN: 009 070 384ABN: 58 009 070 384
Registration Date: 30 June 1983

This company subsequently changed its name to INOVIQ LTD. You should refer to that name for Legal Status.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

This company subsequently changed its name and is now INOVIQ LTD. You should refer to that name for Capital Gains Tax Status.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

BARD1 LIFE SCIENCES LIMITED(BD1)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

	FROM	TO
INOVIQ LTD	09/12/2021
BARD1 LIFE SCIENCES LIMITED	14/06/2016	09/12/2021
EUROGOLD LIMITED	28/05/2002	14/06/2016
ESMERALDA EXPLORATION LIMITED		28/05/2002

Shareholder links

Our website ranking of BD1:

(5 out of 5)

COMPANY WEBSITE:

BD1 website

BD1 email

BD1 investorRelations

BD1 announcements

BD1 annualreports

BD1 directors

REGISTRY:

Level 17, 221 St Georges Terrace, Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000BD12

Address: Unit 202, Level 2 39 Mends Street South Perth WA 6151
Tel: +61 8 9381 9550 Fax: +61 8 9388 7559

Date first listed: 18/04/1991
Company Secretary:
Sector: Health Care Equipment & Services Industry Group: XMJ
Activities: Developing and commercialising a blood test for lung cancer detection.

News & Events

Expand this box to read and print

name changed to Inoviq Ltd	09/12/2021
we understand that on or about this date the company consolidated its shares 1 for 30	27/11/2020
The suspension of trading in the securities of Bard1 Life Sciences Limited will be lifted immediately, following receipt of a response to an ASX Query.	18/05/2018
The company issues a response to ASX Price Query.	18/05/2018
The company signed an assay development agreement with Thermo Fisher Scientific for Multiplex Research-Use-Only custom assay development. A RUO BARD1 autoantibody assay will be developed using ProcartaPlex Technology for performance on Luminex instrumentation. The first application of the ProcartaPlex Technology is to the BARD1-Ovarian test in development for detection of ovarian cancer.	18/05/2018
The securities of Bard1 Life Sciences Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding a development contract.	14/05/2018
The securities of BARD1 Life Sciences Limited (previously Eurogold Limited) (the "Company") will be reinstated to official quotation from the commencement of trading on 20 June 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. 322,493,350 fully paid ordinary shares	17/06/2016
name changed from Eurogold Limited	14/06/2016

OFX Transferring Money Internationally to Free

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
21/10/2021	Philip Powell	40,000	$1.085	$43,400.00
04/12/2020	Geoffrey Cumming	9,333	$0.757	$7,066.00
02/12/2020	Max Johnston	30,000	$0.680	$20,385.00
02/12/2020	Philip Powell	70,000	$0.697	$48,762.00
22/11/2019	Irmgard Irminger-Finger	347,663	$0.034	$11,729.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Geoffrey Cumming	Non Exec Chairman	28/07/2020
Leearne Hinch	CEO	07/11/2016
David A. Taylor	Joint Managing Director	28/09/2001
Allan Cripps	Non Exec Director	25/01/2020
Philip Powell	Director	18/06/2019
Max Johnston	Director	18/06/2019

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.